2024
Radiomic Features of Acute Cerebral Hemorrhage on Non-Contrast CT Associated with Patient Survival
Zaman S, Dierksen F, Knapp A, Haider S, Karam G, Qureshi A, Falcone G, Sheth K, Payabvash S. Radiomic Features of Acute Cerebral Hemorrhage on Non-Contrast CT Associated with Patient Survival. Diagnostics 2024, 14: 944. PMID: 38732358, PMCID: PMC11083693, DOI: 10.3390/diagnostics14090944.Peer-Reviewed Original ResearchInternational Normalized RatioArea under the curveNational Institutes of Health Stroke ScaleIntracerebral hemorrhageRadiomic featuresAntihypertensive Treatment of Acute Cerebral Hemorrhage IINon-contrast head CT scanBaseline International Normalized RatioAssociated with worse survival outcomesAcute intracerebral hemorrhageSupratentorial intracerebral hemorrhageWorse survival outcomesKaplan-Meier analysisHead CT scanCox proportional hazards modelsPredictors of mortalityAcute cerebral hemorrhageReceiver Operating Characteristic (ROC) analysisFirst-order energyHigher mortality riskProportional hazards modelHealth Stroke ScaleCT radiomicsHematoma expansionPost-ICHTime-Dependent Changes in Hematoma Expansion Rate after Supratentorial Intracerebral Hemorrhage and Its Relationship with Neurological Deterioration and Functional Outcome
Karam G, Chen M, Zeevi D, Harms B, Torres-Lopez V, Rivier C, Malhotra A, de Havenon A, Falcone G, Sheth K, Payabvash S. Time-Dependent Changes in Hematoma Expansion Rate after Supratentorial Intracerebral Hemorrhage and Its Relationship with Neurological Deterioration and Functional Outcome. Diagnostics 2024, 14: 308. PMID: 38337824, PMCID: PMC10855868, DOI: 10.3390/diagnostics14030308.Peer-Reviewed Original ResearchPredictors of NDSupratentorial intracerebral hemorrhageHematoma expansionIntracerebral hemorrhageNeurological deteriorationPoor outcomeNIH Stroke ScalePost-ICHFunctional outcomesMild symptomsHematoma expansion ratesIntracerebral hemorrhage onsetAssociation of HEModifiable risk factorsGlasgow Coma ScaleBaseline CTHematoma growthConsecutive patientsHead CTSCAN-3Follow-upRate of HEComa ScaleRisk factorsHematomaPeri-hematomal edema shape features related to 3-month outcome in acute supratentorial intracerebral hemorrhage
Dierksen F, Tran A, Zeevi T, Maier I, Qureshi A, Sanelli P, Werring D, Malhotra A, Falcone G, Sheth K, Payabvash S. Peri-hematomal edema shape features related to 3-month outcome in acute supratentorial intracerebral hemorrhage. European Stroke Journal 2024, 9: 383-390. PMID: 38179883, PMCID: PMC11318427, DOI: 10.1177/23969873231223814.Peer-Reviewed Original ResearchNIH Stroke ScaleGlasgow Coma ScaleAssociation of baselineIntracerebral hemorrhagePerihematomal edemaHematoma volumeAcute supratentorial intracerebral hemorrhageNon-traumatic intracerebral hemorrhageSecondary brain injuryAcute ICH patientsIndependent prognostic factorSupratentorial intracerebral hemorrhageAdmission NIH Stroke ScalePotential treatment targetRankin scoreStroke ScaleIndependent predictorsPatient agePrognostic factorsComa ScaleMultivariable analysisICH patientsPrognostic valueBrain injuryFavorable outcome
2023
Clinical implications of Peri-hematomal edema microperfusion fraction in intracerebral hemorrhage intravoxel incoherent motion imaging – A pilot study
Abou Karam G, Tharmaseelan H, Aboian M, Malhotra A, Gilmore E, Falcone G, de Havenon A, Sheth K, Payabvash S. Clinical implications of Peri-hematomal edema microperfusion fraction in intracerebral hemorrhage intravoxel incoherent motion imaging – A pilot study. Journal Of Stroke And Cerebrovascular Diseases 2023, 32: 107375. PMID: 37738914, PMCID: PMC10591892, DOI: 10.1016/j.jstrokecerebrovasdis.2023.107375.Peer-Reviewed Original ResearchConceptsModified Rankin ScaleSecondary brain injuryIntracerebral hemorrhagePerihematomal edemaSubacute intracerebral hemorrhageIntravoxel incoherent motion imagingAdmission NIHSSBrain injuryMedian baseline National InstitutesPilot studyBaseline National InstitutesHealth Stroke ScalePerfusion fractionSupratentorial intracerebral hemorrhageIVIM metricsIncoherent motion imagingStroke ScaleNeuroprotective therapiesParenchymal injuryRankin ScaleRisk patientsConsecutive patientsUnivariable analysisPoor outcomeICH volumeRadiomic markers of intracerebral hemorrhage expansion on non-contrast CT: independent validation and comparison with visual markers
Haider S, Qureshi A, Jain A, Tharmaseelan H, Berson E, Zeevi T, Werring D, Gross M, Mak A, Malhotra A, Sansing L, Falcone G, Sheth K, Payabvash S. Radiomic markers of intracerebral hemorrhage expansion on non-contrast CT: independent validation and comparison with visual markers. Frontiers In Neuroscience 2023, 17: 1225342. PMID: 37655013, PMCID: PMC10467422, DOI: 10.3389/fnins.2023.1225342.Peer-Reviewed Original ResearchIndependent validation cohortIntracerebral hemorrhageRadiomic featuresValidation cohortClinical variablesHematoma expansionSpontaneous supratentorial intracerebral hemorrhageNon-contrast head CTSupratentorial intracerebral hemorrhageTomography (CT) of patientsNon-contrast headFuture clinical trialsNon-contrast CTIntracerebral Hemorrhage ExpansionHigh predictive valueBAT scoreHypertensive patientsClinical predictorsPrognostic relevanceFunctional outcomeClinical trialsHead CTHemorrhage expansionClinical trial datasetDiscovery cohort
2019
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial
Selim M, Foster L, Moy C, Xi G, Hill M, Morgenstern L, Greenberg S, James M, Singh V, Clark W, Norton C, Palesch Y, Yeatts S, Investigators I, Dolan M, Yeh E, Sheth K, Kunze K, Muehlschlegel S, Nieto I, Claassen J, Falo C, Huang D, Beckwith A, Messe S, Yates M, O'Phelan K, Escobar A, Becker K, Tanzi P, Gonzales N, Tremont C, Venkatasubramanian C, Thiessen R, Save S, Verrault S, Collard K, DeGeorgia M, Cwiklinski V, Thompson B, Wasilewski L, Andrews C, Burfeind R, Torbey M, Hamed M, Butcher K, Sivakumar L, Varelas N, Mays-Wilson K, Leira E, Olalde H, Silliman S, Calhoun R, Dangayach N, Renvill R, Malhotra R, Kordesch K, Lord A, Calahan T, Geocadin R, Parish M, Frey J, Harrigan M, Leifer D, Mathias R, Schneck M, Bernier T, Gonzales-Arias S, Elysee J, Lopez G, Volgi J, Brown R, Jasak S, Phillips S, Jarrett J, Gomes J, McBride M, Aldrich F, Aldrich C, Kornbluth J, Bettle M, Goldstein J, Tirrell G, Shaw Q, Jonczak K. Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. The Lancet Neurology 2019, 18: 428-438. PMID: 30898550, PMCID: PMC6494117, DOI: 10.1016/s1474-4422(19)30069-9.Peer-Reviewed Original ResearchConceptsBetter clinical outcomesPhase 2 trialSerious adverse eventsRankin Scale scorePlacebo groupIntracerebral hemorrhagePrimary outcomeClinical outcomesDay 90Deferoxamine mesylateModified intentionTreat populationAdverse eventsUS National InstitutesDouble-blind phase 2 trialScale scorePhase 3 efficacy trialsModified Rankin Scale scoreEfficacy of deferoxaminePhase 3 trialSupratentorial intracerebral hemorrhageAbsolute risk differenceProportion of participantsNational InstituteIron chelator deferoxamineEfficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial
Hanley D, Thompson R, Rosenblum M, Yenokyan G, Lane K, McBee N, Mayo S, Bistran-Hall A, Gandhi D, Mould W, Ullman N, Ali H, Carhuapoma J, Kase C, Lees K, Dawson J, Wilson A, Betz J, Sugar E, Hao Y, Avadhani R, Caron J, Harrigan M, Carlson A, Bulters D, LeDoux D, Huang J, Cobb C, Gupta G, Kitagawa R, Chicoine M, Patel H, Dodd R, Camarata P, Wolfe S, Stadnik A, Money P, Mitchell P, Sarabia R, Harnof S, Barzo P, Unterberg A, Teitelbaum J, Wang W, Anderson C, Mendelow A, Gregson B, Janis S, Vespa P, Ziai W, Zuccarello M, Awad I, Investigators M, Abdul-Rahim A, Abou-Hamden A, Abraham M, Ahmed A, Alba C, Aldrich E, Altschul D, Amin-Hanjani S, Anderson D, Ansari S, Antezana D, Ardelt A, Arikan F, Baguena M, Baker A, Barrer S, Becker K, Bergman T, Boström A, Braun J, Brindley P, Broaddus W, Brown R, Buki A, Cao B, Cao Y, Carrion-Penagos J, Chalela J, Chang T, Chorro I, Chowdhry S, Corral L, Csiba L, Davies J, Díaz A, Derdeyn C, Diringer M, Dlugash R, Ecker R, Economas T, Enriquez P, Ezer E, Fan Y, Feng H, Franz D, Freeman W, Fusco M, Galicich W, Gelea M, Goldstein J, Gonzalez A, Grabarits C, Greenberg S, Gress D, Gu E, Hall C, Hernandez F, Hoesch R, Hoh B, Houser J, Hu R, Huang Y, Hussain M, Insinga S, Jadhav A, Jaffe J, Jahromi B, Jallo J, James M, James R, Jankowitz B, Jeon E, Jichici D, Jonczak K, Jonker B, Karlen N, Keric N, Kerz T, Knopman J, Koenig C, Krishnamurthy S, Kumar A, Kureshi I, Laidlaw J, Lakhanpal A, Latorre J, Leifer D, Leiphart J, Lenington S, Li Y, Lopez G, Lovick D, Lumenta C, Luo J, Maas M, MacDonald J, MacKenzie L, Madan V, Majkowski R, Major O, Malhorta R, Malkoff M, Mangat H, Maswadeh A, Matouk C, McArthur K, McCaul S, Medow J, Mezey G, Mighty J, Miller D, Mohan K, Muir K, Muñoz L, Nakaji P, Nee A, Nekoovaght-Tak S, Nyquist P, O'Kane R, Okasha M, O'Kelly C, Ostapkovich N, Pandey A, Parry-Jones A, Perla K, Pollack A, Polster S, Pouratian N, Quinn T, Rajajee V, Reddy K, Rehman M, Reimer R, Rincon F, Rybinnik I, Sanchez B, Sansing L, Schneck M, Schuerer L, Schul D, Schweitzer J, Seder D, Seyfried D, Sheth K, Spiotta A, Stechison M, Szabo K, Tamayo G, Tanczos K, Taussky P, Terry J, Testai F, Thomas K, Thompson C, Thompson G, Torner J, Tran H, Tucker K, Ungar L, Varelas P, Vargas N, Vatter H, Venkatasubramanian C, Vermillion K, Vollmer D, Wang Y, Wang Y, Wen J, Whitworth L, Willis B, Wrencher M, Wright S, Xu Y, Yanase L, Yi X, Yu Z, Zomorodi A. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. The Lancet 2019, 393: 1021-1032. PMID: 30739747, PMCID: PMC6894906, DOI: 10.1016/s0140-6736(19)30195-3.Peer-Reviewed Original ResearchConceptsStandard medical care groupMedical care groupStandard medical carePhase 3 trialProportion of patientsSerious adverse eventsSupratentorial intracerebral hemorrhageCare groupIntracerebral hemorrhageMedical careAdverse eventsMRS scoreFunctional outcomeComputer-generated number sequenceModified Rankin Scale scoreInvasive catheter evacuationPrespecified baseline covariatesPrimary efficacy outcomeLarge intracerebral hemorrhageGood functional outcomeRankin Scale scoreNumber of patientsIntracerebral hemorrhage evacuationLogistic regression modelsBlinded endpoint